Comparison of Efficacy of Microneedling With Platelet Rich Plasma Vs Microneedling With Topical Insulin in the Treatment of Acne Scars

NCT06978361 | Recruiting

• 1 other identifier: 938/DME/KMC
• Study Type: interventional
• Target: 116
• Locations: 1 country
• Sites: 1

Brief Summary

This study compares the outcome of two procedures for the treatment of atrophic acne scars.

Conditions

Post-acne Atrophic Scars

Keywords

Post-acne atrophic scars; Microneedling with autologous Platelet- Rich Plasma; Microneedling with topical insulin

Outcome Measures

Primary Outcomes (1)

• Efficacy of treatment

  Efficacy will be determined by using the Goodman and Baron's Scarring Grading System as" Percentage of decrease in acne scar grade" i.e calculated through subtracting post treatment grade from pre treatment grade and then multiplying it with 100 in both treatment groups .

  6 months

Study Arms (2)

Group A , Microneedling with autologous PRP

EXPERIMENTAL

Patients in group A will undergo microneedling with autologous PRP i.e cleansing of the treatment area with an antiseptic solution will be performed.Topical anesthetic will be applied to the area for 20-30 mins .Approximately 10ml of blood will be drawn into sterile tubes. blood sample will be placed in centrifuge 10-15mins which separates the blood components, allowing for the collection of PRP .Then sterile microneedling device will be used to begin the procedure by adjusting the needle depth according to scar severity.Controlled microinjuries to the skin will be made by moving the device in a systematic pattern over the treatment area .After microneedling ,immediately harvested PRP will be applied to the treated area ,allowing it to penetrate into the microinjuries .Patient will be asked for consideration of aftercare instructions ,including avoiding sun exposure , harsh skincare products and strenuous exercise for few days.

Procedure: Microneedling with autologous Platelet Rich Plasma

Group B , Microneedling with Topical insulin

EXPERIMENTAL

Patients in group B will undergo microneedling with Topical insulin i.e cleansing of the treatment area with an antiseptic solution will be performed.Topical anesthetic will be applied to the area for 20-30 mins to reduce discomfort during the procedure.Then sterile microneedling device will be used to begin the procedure by adjusting the needle depth according to scar severity.Controlled microinjuries to the skin will be made by moving the device in a systematic pattern over the treatment area .After microneedling Insulin (Regular) will be applied immediately to the treated area. insulin will be allowed to penetrate into the microinjuries created by the microneedling for about 30 mins . Patient will be asked for consideration of aftercare instructions ,including avoiding sun exposure , harsh skincare products and strenuous exercise for few days.

Procedure: Microneedling with topical insulin

Interventions

Microneedling with autologous Platelet Rich Plasma PROCEDURE

Patients in group A will undergo Microneedling with autologous PRP

Group A , Microneedling with autologous PRP

Microneedling with topical insulin PROCEDURE

Patients in group B will undergo Microneedling with Topical insulin ( regular).

Group B , Microneedling with Topical insulin

Eligibility Criteria

• Age: 18 Years - 50 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Patients confirmed with post-acne atrophic scars . No prior treatment for scars in last 6 months.

You may not qualify if:

• Patient with active acne or other skin conditions (e.g eczema , psoriasis). Patients on oral or topical retinoids. Pregnant or lactating Mothers. Patients with recurrent herpes simplex infection. Previous Hx of keloids / hypertrophic scarring. Deranged blood glucose levels. Bleeding disorders

Sponsors & Collaborators

• Khyber Teaching Hospital: lead

Study Sites (1)

Khyber Teaching Hospital

Peshawar, KPK ,Pakistan, 25000, Pakistan

RECRUITING

MeSH Terms

Interventions

Percutaneous Collagen Induction; Insulin

Intervention Hierarchy (Ancestors)

Complementary Therapies; Therapeutics; Physical Therapy Modalities; Punctures; Rehabilitation; Proinsulin; Insulins; Pancreatic Hormones; Peptide Hormones; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Peptides; Amino Acids, Peptides, and Proteins

Central Study Contacts

Soaiba Naeem, MBBS

CONTACT

+923139493991; soaiba91@gmail.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Doctor

Study Record Dates

• First Submitted: May 10, 2025
• First Posted: May 18, 2025
• Study Start: March 1, 2025
• Primary Completion: December 31, 2025
• Study Completion: December 31, 2025
• Last Updated: May 18, 2025

Record last verified: 2025-02

Data Sharing

• IPD Sharing: Will not share

Locations

PA (1)